Z12.5 – Encounter for screening for malignant neoplasm of prostate

Z12.5 – Encounter for screening for malignant neoplasm of prostate

Discover Z12.5: Prostate cancer screening encounter code. Early detection saves lives. Understand its clinical description, billable status, and FAQs.

By Patricia Buenaventura on Aug 8, 2025.

Fact Checked by Karina Jimenea.

Use Code

Z12.5 diagnosis code: Encounter for screening for malignant neoplasm of prostate

The ICD-10-CM code Z12.5 represents the encounter for screening for malignant neoplasm of the prostate (prostate gland). This code is used when a patient seeks medical attention to undergo prostate cancer screening. Here are key points about this diagnosis code:

  • The primary purpose of using code Z12.5 is to encourage early detection and diagnosis of prostate cancer through routine screening.
  • This code applies to asymptomatic patients and those without known prostate-related symptoms.
  • The encounter can occur in various healthcare settings, such as primary care offices, urology clinics, or specialized cancer centers.
  • Screening methods for prostate cancer include digital rectal examination (DRE), prostate-specific antigen (PSA) testing, or a combination of both.
  • The code is only applicable to male patients and should not be used for diagnostic evaluations or follow-up of confirmed prostate cancer cases.

Is Z12.5 billable?

Yes, the Z12.5 code is billable and covered by the Centers for Medicare & Medicaid Services. Insurance providers typically cover preventive services like prostate cancer screening, including the associated evaluation and management visit. However, it is important to verify coverage with individual insurance plans and adhere to their specific guidelines.

Clinical information

  • Prostate cancer is the most common cancer in males and the second leading cause of cancer-related deaths among men in some regions.
  • Risk factors for prostate cancer include age (increasing incidence with older age), family history, African-American ethnicity, and certain genetic mutations.
  • Routine screening for prostate cancer typically involves digital rectal examination (DRE) and prostate-specific antigen (PSA) testing.
  • The American Cancer Society recommends discussing the potential benefits and limitations of screening patients to facilitate informed decision-making.
  • PSA screening may have limitations, including the potential for false positives or false negatives, leading to further evaluations, such as prostate biopsies.
  • Early detection through screening allows for timely treatment and may improve the chances of successful outcomes for prostate cancer patients.

Synonyms include

  • Encounter for screening for malignant neoplasm of the prostate
  • Screening for prostate cancer
  • Prostate cancer screening
  • Prostate cancer screening visit
  • Screening exam for prostate cancer

Other ICD-10 codes commonly used for encounter for screening for malignant neoplasm

Here are commonly used ICD-10 codes related to the encounter for screening for other malignant neoplasms:

  • Z12.0 - Encounter for screening for malignant neoplasm of stomach
  • Z12.11 - Encounter for screening for malignant neoplasm of colon
  • Z12.12 - Encounter for screening for malignant neoplasm of rectum
  • Z12.3 - Encounter for screening for malignant neoplasm of breast
  • Z12.71 - Encounter for screening for malignant neoplasm of testis
  • Z12.72 - Encounter for screening for malignant neoplasm of vagina
  • Z12.73 - Encounter for screening for malignant neoplasm of ovary
  • Z12.83 - Encounter for screening for malignant neoplasm of skin
  • Z12.89 - Encounter for screening for malignant neoplasm of other sites
  • Z12.9 - Encounter for screening for malignant neoplasm, site unspecified

Commonly asked questions

he American Cancer Society recommends discussing prostate cancer screening with patients starting at age 50 for most men. However, for individuals with a higher risk, such as those with a family history or African-American ethnicity, screening discussions may begin at age 45 or earlier.

Prostate cancer screening may lead to early detection and timely treatment, potentially improving outcomes. However, it can also result in false positives, leading to unnecessary tests or procedures. Patients should discuss the risks and benefits with their healthcare providers to make informed decisions.

No, the Z12.5 code is specifically for encounter screening purposes and should not be used for patients with confirmed prostate cancer diagnoses. Separate codes exist to capture the appropriate encounters for evaluating, managing, and treating confirmed diseases.

Related ICDs

EHR and practice management software

Get started for free

*No credit card required

Start for free

Free

$0/usd

Unlimited clients

Telehealth

1GB of storage

Client portal text

Automated billing and online payments